

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

**Claims 1-47 (Canceled)**

**Claim 48 (New)** A method of enhancing wound healing in a patient, the method comprising administering an effective amount of a mutein of human basic fibroblast growth factor or a biologically active peptide thereof,

wherein the mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprises the substitution of a neutral and/or hydrophobic amino acid for one or more of the following: (a) Glutamate 89; or (b) Aspartate 101; or (c) Leucine 137.

**Claim 49 (New)** The method of claim 48, wherein the wound healing is selected from the group consisting of burns, surgical incisions, lacerations, ulcers, and traumas.

**Claim 50 (New)** The mutein of claim 48 which comprises the substitution of a hydrophobic amino acid for Glu89.

**Claim 51 (New)** The mutein of claim 48 which comprises the substitution of a hydrophobic amino acid for Asp101.

**Claim 52 (New)** The mutein of claim 48 which comprises the substitution of a hydrophobic amino acid for Leu137.

**Claim 53 (New)** The mutein of claim 48 which comprises the substitution of a neutral amino acid for Glu89.

**Claim 54 (New)** The mutein of claim 48 which comprises the substitution of a neutral amino acid for Asp101.

**Claim 55 (New)** The mutein of claim 48 which comprises the substitution of a neutral amino acid for Leu137.

**Claim 56 (New)** The mutein of claim 48 wherein a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.

**Claim 57 (New)** The mutein of claim 48 which is human basic fibroblast growth factor [Tyr101].

**Claim 58 (New)** The mutein of claim 48 which is human basic fibroblast growth factor [Tyr137].

**Claim 59 (New)** The mutein of claim 48 which is human basic fibroblast growth factor [Tyr89, 101].

**Claim 60 (New)** The mutein of claim 48 which is human basic fibroblast growth factor [Tyr89, 137].

**Claim 61 (New)** The mutein of claim 48 which is human basic fibroblast growth factor [Tyr101, 137].

**Claim 62 (New)** The mutein of claim 48 which is human basic fibroblast growth factor [Tyr89, 101 137].

**Claim 63 (New)** The mutein of claim 48, wherein the mutein is administered topically.

**Claim 64 (New)** The mutein of claim 48, wherein the mutein is administered parenterally.

**Claim 65 (New)** A method of stimulating fibroblast cell proliferation in a patient, wherein the patient has heart disease, the method comprising administering an effective amount of a mutein of human basic fibroblast growth factor or a biologically active peptide thereof,

wherein the mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprises the substitution of a neutral and/or hydrophobic amino acid for one or more of the following: (a) Glutamate 89; or (b) Aspartate 101; or (c) Leucine 137.

**Claim 66 (New)** The method of claim 65, wherein the patient has coronary artery disease.

**Claim 67 (New)** The method of claim 65, wherein the patient has myocardial infarction.

**Claim 68 (New)** The mutein of claim 65, which comprises the substitution of a hydrophobic amino acid for Glu89.

**Claim 69 (New)** The mutein of claim 65, which comprises the substitution of a hydrophobic amino acid for Asp101.

**Claim 70 (New)** The mutein of claim 65, which comprises the substitution of a hydrophobic amino acid for Leu137.

**Claim 71 (New)** The mutein of claim 65, which comprises the substitution of a neutral amino acid for Glu89.

**Claim 72 (New)** The mutein of claim 65, which comprises the substitution of a neutral amino acid for Asp101.

**Claim 73 (New)** The mutein of claim 65, which comprises the substitution of a neutral amino acid for Leu137.

**Claim 74 (New)** The mutein of claim 65, wherein a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.

**Claim 75 (New)** The mutein of claim 65, which is human basic fibroblast growth factor [Tyr101].

**Claim 76 (New)** The mutein of claim 65, which is human basic fibroblast growth factor [Tyr137].

**Claim 77 (New)** The mutein of claim 65, which is human basic fibroblast growth factor [Tyr89, 101].

**Claim 78 (New)** The mutein of claim 65, which is human basic fibroblast growth factor [Tyr89, 137].

**Claim 79 (New)** The mutein of claim 65, which is human basic fibroblast growth factor [Tyr101, 137].

**Claim 80 (New)** The mutein of claim 65, which is human basic fibroblast growth factor [Tyr89, 101 137].

**Claim 81 (New)** The mutein of claim 65, wherein the mutein is administered topically.

**Claim 82 (New)** The mutein of claim 65, wherein the mutein is administered parenterally.

**Claim 83 (New)** A method of stimulating fibroblast cell proliferation in a patient, wherein the patient has peripheral vascular disease, the method comprising administering an effective amount of a mutein of human basic fibroblast growth factor or a biologically active peptide thereof,

wherein the mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprises the substitution of a neutral and/or hydrophobic amino acid for one or more of the following: (a) Glutamate 89; or (b) Aspartate 101; or (c) Leucine 137.

**Claim 84 (New)** The mutein of claim 83, which comprises the substitution of a hydrophobic amino acid for Glu89.

**Claim 85 (New)** The mutein of claim 83, which comprises the substitution of a hydrophobic amino acid for Asp101.

**Claim 86 (New)** The mutein of claim 83, which comprises the substitution of a hydrophobic amino acid for Leu137.

**Claim 87 (New)** The mutein of claim 83, which comprises the substitution of a neutral amino acid for Glu89.

**Claim 88 (New)** The mutein of claim 83, which comprises the substitution of a neutral amino acid for Asp101.

**Claim 89 (New)** The mutein of claim 83, which comprises the substitution of a neutral amino acid for Leu137.

**Claim 90 (New)** The mutein of claim 83, wherein a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.

**Claim 91 (New)** The mutein of claim 83, which is human basic fibroblast growth factor [Tyr101].

**Claim 92 (New)** The mutein of claim 83, which is human basic fibroblast growth factor [Tyr137].

**Claim 93 (New)** The mutein of claim 83, which is human basic fibroblast growth factor [Tyr89, 101].

**Claim 94 (New)** The mutein of claim 83, which is human basic fibroblast growth factor [Tyr89, 137].

**Claim 95 (New)** The mutein of claim 83, which is human basic fibroblast growth factor [Tyr101, 137].

**Claim 96 (New)** The mutein of claim 83, which is human basic fibroblast growth factor [Tyr89, 101 137].

**Claim 97 (New)** The mutein of claim 83, wherein the mutein is administered topically.

**Claim 98 (New)** The mutein of claim 83, wherein the mutein is administered parenterally.

**Claim 99 (New)** A method of stimulating fibroblast cell proliferation in a patient, wherein the patient has neural injury, the method comprising administering an effective amount of a mutein of human basic fibroblast growth factor or a biologically active peptide thereof,

wherein the mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprises the substitution of a neutral and/or hydrophobic amino acid for one or more of the following: (a) Glutamate 89; or (b) Aspartate 101; or (c) Leucine 137.

**Claim 100 (New)** The mutein of claim 99, which comprises the substitution of a hydrophobic amino acid for Glu89.

**Claim 101 (New)** The mutein of claim 99, which comprises the substitution of a hydrophobic amino acid for Asp101.

**Claim 102 (New)** The mutein of claim 99, which comprises the substitution of a hydrophobic amino acid for Leu137.

**Claim 103 (New)** The mutein of claim 99, which comprises the substitution of a neutral amino acid for Glu89.

**Claim 104 (New)** The mutein of claim 99, which comprises the substitution of a neutral amino acid for Asp101.

**Claim 105 (New)** The mutein of claim 99, which comprises the substitution of a neutral amino acid for Leu137.

**Claim 106 (New)** The mutein of claim 99, wherein a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.

**Claim 107 (New)** The mutein of claim 99, which is human basic fibroblast growth factor [Tyr101].

**Claim 108 (New)** The mutein of claim 99, which is human basic fibroblast growth factor [Tyr137].

**Claim 109 (New)** The mutein of claim 99, which is human basic fibroblast growth factor [Tyr89, 101].

**Claim 110 (New)** The mutein of claim 99, which is human basic fibroblast growth factor [Tyr89, 137].

**Claim 111 (New)** The mutein of claim 99, which is human basic fibroblast growth factor [Tyr101, 137].

**Claim 112 (New)** The mutein of claim 99, which is human basic fibroblast growth factor [Tyr89, 101, 137].

**Claim 113 (New)** The mutein of claim 99, wherein the mutein is administered topically.

**Claim 114 (New)** The mutein of claim 99, wherein the mutein is administered parenterally.

**Claim 115 (New)** A method of stimulating fibroblast cell proliferation in a patient, wherein the patient has ischemia, the method comprising administering an effective amount of a mutein of human basic fibroblast growth factor or a biologically active peptide thereof,

wherein the mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprises the substitution of a neutral and/or hydrophobic amino acid for one or more of the following: (a) Glutamate 89; or (b) Aspartate 101; or (c) Leucine 137.

**Claim 116 (New)** The mutein of claim 115, which comprises the substitution of a hydrophobic amino acid for Glu89.

**Claim 117 (New)** The mutein of claim 115, which comprises the substitution of a hydrophobic amino acid for Asp101.

**Claim 118 (New)** The mutein of claim 115, which comprises the substitution of a hydrophobic amino acid for Leu137.

**Claim 119 (New)** The mutein of claim 115, which comprises the substitution of a neutral amino acid for Glu89.

**Claim 120 (New)** The mutein of claim 115, which comprises the substitution of a neutral amino acid for Asp101.

**Claim 121 (New)** The mutein of claim 115, which comprises the substitution of a neutral amino acid for Leu137.

**Claim 122 (New)** The mutein of claim 115, wherein a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.

**Claim 123 (New)** The mutein of claim 115, which is human basic fibroblast growth factor [Tyr101].

**Claim 124 (New)** The mutein of claim 115, which is human basic fibroblast growth factor [Tyr137].

**Claim 125 (New)** The mutein of claim 115, which is human basic fibroblast growth factor [Tyr89, 101].

**Claim 126 (New)** The mutein of claim 115, which is human basic fibroblast growth factor [Tyr89, 137].

**Claim 127 (New)** The mutein of claim 115, which is human basic fibroblast growth factor [Tyr101, 137].

**Claim 128 (New)** The mutein of claim 115, which is human basic fibroblast growth factor [Tyr89, 101 137].

**Claim 129 (New)** The mutein of claim 115, wherein the mutein is administered topically.

**Claim 130 (New)** The mutein of claim 115, wherein the mutein is administered parenterally.

**REMARKS/ARGUMENTS**

With this amendment, claims 1-47 have been cancelled, and new claims 48 to 130 have been added. Entry of the amendment is respectfully requested. With entry of this amendment, claims 48 to 130 are pending. Support for claims 48 to 130 can be found throughout the specification, and for example, in the specification as cited below. No new matter has been added by way of this preliminary amendment.

Support for claims 48-64 can be found throughout the specification and, for example, at page 18, lines 6-18 and at page 18, line 25 through page 19, line 11. Additional support can be found at page 20, lines 18-30.


Support for claims 65-82 can be found throughout the specification and, for example, at page 18, lines 6-18 and at page 18, line 25 through page 19, line 11. Further support can be found at page 20, lines 18-30. Additional support can be found in the examples.

Support for claims 83-98 can be found throughout the specification and, for example, at page 18, lines 6-18 and at page 18, line 25 through page 19, line 11. Further support can be found at page 20, lines 18-30. Additional support can be found in the examples.

Support for claims 99-114 can be found throughout the specification and, for example, at page 18, lines 6-18 and at page 18, line 25 through page 19, line 11. Further support can be found at page 20, lines 18-30. Additional support can be found in the examples.

Support for claims 115-130 can be found throughout the specification and, for example, at page 18, lines 6-18 and at page 18, line 25 through page 19, line 11. Further support can be found at page 20, lines 18-30. Additional support can be found in the examples.

Date: February 23, 2004

  
Andrew T. Serafini  
Registration No. 41,303

Woodcock Washburn LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439